title: Budget Impact Analysis of the Introduction of New Therapeutic Agents for the Treatment of Metastatic Castration Resistant Prostate Cancer (MCRPC) Patients After Docetaxel Failure in the Brazilian Private Health System.
authors.affiliation: Janssen-Cilag Farmaceutica, São Paulo, Brazil.
authors.forename: E
authors.initials: E
authors.lastname: Asano
authors.affiliation: Janssen-Cilag Farmaceutica, São Paulo, Brazil.
authors.forename: V
authors.initials: V
authors.lastname: Vitale